Induction of Robust Immune Responses against Human Immunodeficiency Virus Is Supported by the Inherent Tropism of Adeno-Associated Virus Type 5 for Dendritic Cells[▽]

Ke-Qin Xin,¹ Hiroaki Mizukami,² Masashi Urabe,² Yoshihiko Toda,¹ Kaori Shinoda,¹
Atsushi Yoshida,¹ Kenji Oomura,¹ Yoshitsugu Kojima,¹ Motohide Ichino,³
Dennis Klinman,⁴ Keiya Ozawa,² and Kenji Okuda^{1*}

Departments of Molecular Biodefense Research¹ and Immunology,³ Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan; Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi-ken 329-0498, Japan²; and Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892⁴

Received 2 May 2006/Accepted 11 September 2006

The ability of adeno-associated virus serotype 1 to 8 (AAV1 to AAV8) vectors expressing the human immunodeficiency virus type 1 (HIV-1) Env gp160 (AAV-HIV) to induce an immune response was evaluated in BALB/c mice. The AAV5 vector showed a higher tropism for both mouse and human dendritic cells (DCs) than did the AAV2 vector, whereas other AAV serotype vectors transduced DCs only poorly. AAV1, AAV5, AAV7, and AAV8 were more highly expressed in muscle cells than AAV2. An immunogenicity study of AAV serotypes indicates that AAV1, AAV5, AAV7, and AAV8 vectors expressing the Env gp160 gene induced higher HIV-specific humoral and cell-mediated immune responses than the AAV2 vector did, with the AAV5 vector producing the best responses. Furthermore, mice injected with DCs that had been transduced ex vivo with an AAV5 vector expressing the gp160 gene elicited higher HIV-specific cell-mediated immune responses than did DCs transduced with AAV1 and AAV2 vectors. We also found that AAV vectors produced by HEK293 cells and insect cells elicit similar levels of antigen-specific immune responses. These results demonstrate that the immunogenicity of AAV vectors depends on their tropism for both antigen-presenting cells (such as DCs) and non-antigen-presenting cells (such as muscular cells) and that AAV5 is a better vector than other AAV serotypes. These results may aid in the development of AAV-based vaccine and gene therapy.

Recombinant adeno-associated viruses (AAVs) have been widely used as gene delivery vectors in animal models (17, 18), and these have entered human clinical trials (34). AAVs have been found in many animal species, including nonhuman primates, canines, fowls, and humans. An increasing number of AAV serotypes have been reported. AAV2, AAV3, and AAV5 are found in humans, while AAV4, AAV7, and AAV8 are found in nonhuman primates (21, 45, 50). The reservoir for AAV1 is unclear because these viruses have not been primarily isolated from tissues; however, reactive antibodies (Abs) against AAV1 have been found to exist in both humans and nonhuman primates (9). AAV6 appears to be a recombinant between AAV1 and AAV2 (60). Most of the current studies involving AAV are based on AAV2 since it was the first available infectious clone (51). The use of AAV2 as a vector to introduce exogenous genes encoding immunogenic proteins for the purpose of vaccination has been explored in several studies conducted by us (65, 66) and other researchers (17, 30, 46, 47). An ex vivo experiment demonstrated that the AAV2 vector can transduce dendritic cells (DCs) and that these cells

then present the AAV-encoded antigen to T cells (46, 65). Other AAV serotypes may have advantages as vaccine vectors because AAV serotypes differ in their tissue and/or cell tropism (23, 25, 30, 47). For example, AAV1 and AAV7 are more efficient than AAV2 for the transduction of skeletal muscle (21, 60), while AAV3 is superior for the transduction of megakaryocytes (27). AAV5 and AAV6 infect apical airway cells more efficiently (24, 68). AAV2, AAV4, and AAV5 infect cells of the central nervous system; however, differences with regard to the distribution and target cell types exist among these three serotypes (68).

AAV is a small, single-stranded DNA virus that lacks an envelope. This virus requires a helper virus to facilitate efficient replication. The genome of wild-type AAV is known to integrate into the human genome at a specific site on chromosome 19q (36). However, in nondividing cells, AAV vector genomes mostly adopt the form of concatameric circular episomes that comprise active transcriptional units (16, 54). AAV is currently the only nonpathogenic viral vector that has been shown to mediate long-term gene expression without causing toxicity in vivo. Using this vector system, exogenous genes have been efficiently transferred into a number of tissues, including brain (18), muscle (29), lung (19), gut (17), liver (55), and eye (37). A human clinical trial of AAV2 has been conducted (34, 41).

The objectives of the present study were (i) to compare the immunogenicities of AAV serotypes (1 to 8) expressing human

* Corresponding author. Mailing address: Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Phone: 81(45)787-2602. Fax: 81 (45)787-2851. E-mail: kokuda@med.yokohama-cu.ac.jp.

[▽] Published ahead of print on 27 September 2006.

FIG. 1. Transduction of mouse muscle by AAV serotype vectors. AAV LacZ-expressing vectors (10^{10} vp) were injected intramuscularly into five mice/group. β -Galactosidase activity in the muscle was examined 2 weeks later using the Beta-Glo Assay System. An asterisk indicates a significant difference between the two groups ($P < 0.05$). RLU, relative light units.

immunodeficiency virus (HIV) Env gp160 in BALB/c mice, (ii) to compare the immunogenicities of AAV serotype vectors produced by HEK293 cells and insect cells, and (iii) to evaluate the mechanisms involved in the observed responses.

MATERIALS AND METHODS

AAV production. AAV vectors were generated as described previously (65, 66). In brief, a *lacZ* gene or a fragment containing HIV Env gp160 and Rev coding genes, which were derived from the HIV IIIB strain, was subcloned into a shuttle vector containing the cytomegalovirus (CMV) promoter, poly(A), and the AAV2 inverted terminal repeat (the AAV5 inverted terminal repeat was used for construction of the AAV5 vector; the AAV2 inverted terminal repeat was used for other AAV serotype vectors). We included a Rev coding gene in the construct because expression of HIV Env gp160 is dependent on Rev protein. This approach resulted in increased HIV Env gp160 protein expression in vitro and enhanced immune responses against HIV Env gp160 in vivo (33). The recombinant shuttle vector was packaged by triple transfection of HEK293 cells with an adenovirus helper plasmid, a chimeric packaging construct in which the AAV2 Rep gene was fused to the cap gene derived from either AAV serotype, and a shuttle vector plasmid to produce pseudotypes AAV2-based AAV1-LacZ, AAV2-LacZ, AAV3-LacZ, AAV4-LacZ, AAV5-LacZ, AAV7-LacZ, and AAV8-LacZ or AAV1-HIV, AAV2-HIV, AAV3-HIV, AAV4-HIV, AAV5-

FIG. 2. Transduction of mouse purified DCs by AAV serotype vectors. (a) Mouse CD11c⁺ DCs were transduced with LacZ-expressing AAV vectors at 10^4 vp/cell (triplicate for each sample). Two days after infection, the cells were stained with X-Gal (upper panel), and the β -galactosidase activity was measured using the Beta-Glo Assay System (bottom panel). The data presented were averaged from three separate experiments. The asterisk indicates a significant difference when AAV2-LacZ-transduced cells were compared to AAV1-LacZ-, AAV3-LacZ-, AAV4-LacZ-, AAV7-LacZ-, and AAV8-LacZ-transduced cells and mock-transduced cells; the double asterisk indicates a significant difference when AAV5-LacZ-transduced cells were compared to AAV2-LacZ-transduced cells. RLU, relative light units. (b) Mouse CD11c⁺ DCs were transduced with AAV-LacZ vectors at 10^3 to 10^5 vp/cell (triplicate for each sample). Two days after transduction, the cells were stained with X-Gal, and the percentages of LacZ-expressing DCs (FDG⁺ CD11c⁺ DCs) were determined. The data presented were averaged from three separate experiments. (c) Enriched immature DCs were transduced with 10^5 vp/cell of various AAV-LacZ vectors (triplicate for each sample). Two days after transduction, the cells were treated with PE-conjugated anti-mouse CD11c Ab and FDG followed by flow cytometric analysis. The data provided represent the fraction of FDG/CD11c dual-positive cells as a percentage of the total population of CD11c⁺ cells. The data presented were averaged from three independent experiments.

HIV, AAV7-HIV, and AAV8-HIV vectors. The AAV vectors were purified by the standard cesium chloride sedimentation method (65, 66). The titer was determined by quantitative DNA dot blot hybridization.

The insect cell-produced AAV vectors (BacAAVs) were generated as described previously (58). The fragment containing the CMV promoter, HIV Env gp160 and Rev coding genes, and poly(A) was excised from the AAV shuttle vector by using NotI; the resulting fragment was inserted into the corresponding site of a baculovirus transfer plasmid between the serotype 2 or 5 inverted terminal repeats. Recombinant baculoviruses were generated by using the Bac-to-Bac baculovirus expression system (Invitrogen, Carlsbad, CA). Recombinant baculoviruses containing the HIV Env gp160 and Rev coding genes; an AAV Rep of serotypes 1, 2, and 5; and an AAV1, AAV2, or AAV5 capsid were used to infect insect cells in order to produce BacAAV1-HIV, BacAAV2-HIV, and BacAAV5-HIV vectors, respectively. The AAV vectors produced were purified by two rounds of ultracentrifugation with a standard cesium chloride density gradient (65, 66). The titer was determined by quantitative DNA dot blot hybridization.

In vivo expression of β -galactosidase. The AAV-LacZ vector (10^{10} viral particles [vp]/mouse) was injected into mouse muscle. Two weeks after the administration, the mouse was sacrificed and the β -galactosidase activity in the muscle was monitored periodically from 1 week through 6 months after administration by using the Beta-Glo Assay System (Promega, Madison, WI).

Mouse DC preparation. DCs were isolated from BALB/c mouse bone marrow, as described previously (7, 62). In brief, the bone marrow was obtained from the tibia and femur of BALB/c mice. The DCs at a density of 5×10^5 cells/ml were

cultured in RPMI 1640 medium containing 10% fetal calf serum, 1 ng/ml recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF; Kirin Beer Corp., Tokyo, Japan), and recombinant interleukin-4 (IL-4) for 6 days.

Transduction of AAV vectors to mouse cells. Immature mouse DCs were stained with phycoerythrin (PE)-conjugated anti-mouse CD11c antibody (clone N418; eBioscience, Boston, MA). The CD11c⁺ DCs were sorted using a MoFlo Cell Sorter (Takara Bio Corp., Tokyo, Japan). The cells were transduced with LacZ-expressing serotype AAV vectors at 10^3 to 10^5 vp/cell for 2 days. The transduced cells were washed with phosphate-buffered saline (PBS) and stained with 40 mM X-Gal (5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside) in staining buffer [5 mM K₃Fe(CN)₆, 5 mM K₄Fe(CN)₆, 2 mM MgCl₂ in PBS] at 37°C for 2 h. The β -galactosidase activity was detected by using the Beta-Glo Assay System (Promega). To count LacZ-expressing cells, the sorted CD11c⁺ DCs were treated with 1 μ M of fluorescein digalactoside (FDG; Molecular Probes, Eugene, OR) followed by flow cytometric analysis (the data are shown in Fig. 2b). The enriched, unsorted DCs were transduced with LacZ-expressing serotype AAV vectors at 10^5 vp/cell for 2 days. The cells were stained with anti-mouse CD11c antibody and treated with FDG followed by flow cytometric analysis (the data are shown in Fig. 2c).

The mouse DCs used in this study were derived from GM-CSF- and IL-4-treated bone marrow cells. To explore the efficiencies of transduction of AAV serotype vectors to hematopoietic cells, unpurified mouse splenocytes and bone marrow cells were transduced with LacZ-expressing serotype AAV vectors at 10^5 vp/cell at 37°C for 2 days. The bone marrow cells were treated with 1 μ M of FDG, and splenocytes were treated with 1 μ M of FDG and PE-conjugated

anti-mouse CD3e (clone 145-2C11), PE-conjugated anti-mouse CD11b (clone M1/70), or PE-conjugated anti-mouse CD19 (clone MB19-1) (all antibodies were from eBioscience) followed by flow cytometric analysis for staining T cells, macrophages, and B cells, respectively.

Human DC preparation. To explore the transduction efficiencies of AAV serotype vectors to human cells, human peripheral blood mononuclear cells (PBMCs) and an enriched population of PBMC-derived immature DCs were prepared as previously described (67). Briefly, human PBMCs were isolated from the blood of a healthy person using Lymphoprep I (Immune Biological Laboratory, Gunma, Japan) according to the manufacturer's instructions. Fresh human PBMCs at 3×10^6 cells/ml in RPMI 1640 medium were dispensed into individual wells of 12-well plates (1 ml/well), which had been previously coated with autologous plasma for 30 min at 37°C. The PBMC cultures were allowed to incubate at 37°C for 1 h. After gentle washing with serum-free RPMI 1640 medium, the adherent cells were cultured in Iscove's modification of Dulbecco modified Eagle medium (2 ml/well) containing human GM-CSF (500 ng/ml) and IL-4 (200 µg/ml) (both from Pierce Biotechnology, Rockford, IL) for 5 days.

Transduction of AAV vectors to human cells. The human PBMCs and an enriched population of PBMC-derived immature DCs were transduced with LacZ-expressing serotype AAV vectors at 10^5 vp/cell at 37°C for 2 days. The AAV-transduced DCs were treated with 1 µM of FDG, and AAV-transduced PBMCs were treated with FDG and PE-conjugated anti-human CD11c (clone 3.9), PE-conjugated anti-human CD3 (clone HIT3a), PE-conjugated anti-human CD11b (clone ICRF44), or PE-conjugated anti-human CD19 (J4-166) (all antibodies were from eBioscience) followed by flow cytometric analysis for staining DCs, T cells, macrophages, and B cells, respectively.

Western blot analysis. To confirm the expression of HIV Env gp160, HEK293 cells were transduced with the AAV vectors encoding the HIV gene in a six-well plate. Two days posttransduction, the cells were washed in PBS and lysed with 0.1 M Tris-HCl (pH 7.8) and 0.125% Nonidet P-40. The cell lysates were mixed with an equal volume of 2× sodium dodecyl sulfate buffer (125 mM Tris-HCl, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol, 0.01% bromophenol blue, and 10% β-mercaptoethanol) and boiled for 10 min. Then the cell lysates were loaded on an 8% polyacrylamide gel and transferred to a Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, England). The HIV gp160 and β-actin proteins were detected using a mouse anti-HIV gp120 monoclonal Ab (Mab) (hybridoma 902; AIDS Research and Reference Reagent Program, National Institutes of Health, Maryland) and an anti-human β-actin Mab (Sigma), respectively. An affinity-purified horseradish peroxidase-labeled anti-mouse immunoglobulin (Ig; ICN Pharmaceuticals, Inc., Solon, OH) was used as the secondary Ab. Protein was detected using the ECL Plus Western Blotting Detection System (Amersham Pharmacia Biotech, Uppsala, Sweden).

Animals and immunization. Eight-week-old BALB/c female mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan). The mice were housed in the animal center located at Yokohama City University and maintained on a 12-h day-night cycle. The mice were intramuscularly (i.m.) immunized three times with 10^{10} particles of the AAV vector at 2-week intervals.

Enzyme-linked immunosorbent assay. The enzyme-linked immunosorbent assay was performed as described elsewhere (63, 65). To summarize, 96-well microtiter plates were coated with 1 µg/ml of HIV_{SF2} gp120 protein (donated by the AIDS Research and Reference Reagent Program, National Institutes of Health) and incubated overnight at 4°C. The wells were blocked with PBS containing 1% bovine serum albumin (BSA) for 2 h at room temperature. They were then treated with 100 µl of serially diluted antisera and incubated for an additional 2 h at 37°C. The bound immunoglobulin was quantified using an affinity-purified horseradish peroxidase-labeled anti-mouse antibody (Sigma). The mean antibody titer was expressed as the reciprocal of the serial serum dilution that exceeded the assay background by 2 standard deviations.

IFN-γ ELISPOT assay. Two weeks after the final immunization, a gamma interferon (IFN-γ) ELISPOT assay was performed as described previously (62). In brief, MultiScreen-IP plates (Millipore, Bedford, MA) were coated with 50 µl of 10-µg/ml purified rat anti-mouse IFN-γ antibody (XMG1.2; PharMingen, San Diego, CA) in PBS overnight at 4°C. The plate was then blocked with PBS containing 5% BSA and 0.025% Tween 20 for 2 h at room temperature. Lymphocytes (1×10^5 to 10×10^5) isolated from the spleen were added to each well in triplicate. The spleen cells were stimulated with or without 10 µg/ml of the HIV V3 peptide (RGPGRAFVTI) for 24 h at 37°C. After incubation, the cells were removed and incubated with 0.5 µg/ml of biotinylated anti-mouse IFN-γ antibody (PharMingen) for 2 h at 37°C, followed by the addition of 100 µl/well of 0.2% alkaline phosphatase-streptavidin (Vector Laboratories, Burlingame, CA) in PBS containing 0.05% Tween 20 and 5% BSA for 1.5 h. Finally, the plate was treated with 50 µl/well of 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium membrane phosphatase (Kirkegaard and Perry Laboratories,

Gaithersburg, MD) at room temperature for 20 min, and the reaction was terminated by holding the plate under running distilled water. The number of spots was counted using a computer-assisted video image analyzer. The results were expressed as spot-forming cells (SFC) per million cells.

Tetramer assay. The tetramer assay was performed as described previously (62–65). The H-2D^d/p18 tetramer (RGPGRAFVTI) labeled with PE was prepared by ProImmune Limited (Oxford, United Kingdom). In brief, mouse splenocytes were incubated with 4% healthy mouse serum in PBS for 15 min at 4°C. The cells were stained with fluorescein isothiocyanate (FITC)-labeled anti-mouse CD8α (Ly-2; PharMingen) at 0.5 µg/10⁶ cells for 30 min at 4°C. After two washes in staining buffer (3% fetal calf serum, 0.1% NaN₃ in PBS), the cells were incubated with the tetramer reagent for 30 min at 4°C and analyzed by flow cytometry.

In vivo CTL assay. The assay was performed as previously described (52). Briefly, cytotoxic T-lymphocyte (CTL) target cells were derived from naïve splenocytes and then pulsed with 10 µg/ml of the HIV V3 peptide (RGPGRAFVTI) or with no peptide at 37°C for 1 h. Peptide-pulsed cells were labeled with a high concentration of carboxyfluorescein diacetate succinimidyl ester (CFSE; 5 µM; Molecular Probes, Eugene, Oreg.), or unpulsed cells were labeled with a low concentration of CFSE (0.5 µM). Cells were then washed and enumerated. For the in vivo CTL assay, 5×10^6 pulsed and 5×10^6 unpulsed cells were combined into a final 200 µl of PBS and intravenously injected into vaccinated mice. Mice were killed 24 h after in vivo target cell incubation. The mouse splenocytes were analyzed by flow cytometry. The percent in vivo killing of CFSE-labeled target cells was defined as the relative loss of such cells after in vivo incubation and thus was taken as the measure of CTL. It was calculated using the formula % killing = $[1 - (\text{unpulsed cells/peptide-pulsed cells from unimmunized control})/(\text{unpulsed cells/peptide-pulsed cells from immunized group})] \times 100$.

Surface expression of HIV gp120 and ex vivo transduction. To investigate whether the AAV-HIV-transduced DCs could present the HIV peptide to T cells, mouse bone marrow-derived DCs were transduced with AAV-HIV vectors at 10^5 vp/cell at 37°C for 2 days. To explore whether HIV gp160 is expressed on the surface of DCs, the AAV-HIV-transduced DCs were stained with HIV gp120 Mab (hybridoma 902) followed by FITC-conjugated rabbit anti-mouse IgG and PE-conjugated anti-mouse CD11c antibody (clone N418; eBioscience). The cells were analyzed by flow cytometry. Enriched mouse DCs were transduced with the AAV-HIV vectors for 2 h and then washed with PBS, and 10^5 cells were intravenously administered to recipient BALB/c mice. One week after the administration, HIV-specific responses were detected by a tetramer assay.

Data analysis. All the values are expressed as means $\pm$ standard errors. Statistical analysis of the experimental data and controls was conducted using one-way factorial analysis of variance. Statistical significance was defined as a value of $P < 0.05$.

RESULTS

Different expression levels of AAV serotype vectors in mouse muscle. Muscular cells are one of the major targets transduced when viral vectors are delivered via the i.m. route. In this study, the relative efficiency with which various AAV serotype vectors were transduced and expressed in vivo was explored. Mice were injected i.m. with AAV serotype vectors carrying the *lacZ* gene. β-Galactosidase activity was monitored periodically from 1 week through 6 months after administration. Results show that the AAV1 and AAV7 vectors elicited significantly higher β-galactosidase activity than the AAV2, AAV3, and AAV4 vectors, with AAV5 and AAV8 yielding intermediate levels of expression at 2 weeks after administration (Fig. 1). We found that AAV expression was maximal 2 to 4 weeks after AAV vector administration, although β-galactosidase activity remained elevated for up to 6 months (data not shown).

Strong tropism of AAV5 for mouse DCs. The ability of each AAV serotype to transduce DCs was then examined. Enriched CD11c⁺ DCs were purified and incubated for 2 days with 10^4 vp/cell of each AAV serotype. Some cells were stained with X-Gal, and others were examined for β-galactosidase expression. As shown in Fig. 2a, very strong X-Gal staining was

FIG. 3. Transduction of mouse unpurified bone marrow cells and splenocytes by AAV serotype vectors. Mouse bone marrow cells and splenocytes were transduced with 10^5 vp/cell of AAV-LacZ vectors. Two days after transduction, the cells were treated with FDG and the splenocytes were stained with anti-mouse CD3 (T cells), anti-mouse CD11b (macrophages), or anti-mouse CD19 (B cells) antibody followed by flow cytometric analysis. Panels show results from one of three independent experiments.

observed in cells treated with AAV5 vector, weaker staining in those treated with AAV2, and none in cells exposed to the other AAV serotypes. Similar results were obtained when purified CD11c⁺ DCs were incubated with 10^3 to 10^5 vp/cell, and X-Gal expression was monitored by flow cytometry. As the dose of vector increased, up to 96.5% of DCs were transduced by the AAV5 vector and 45.7% by the AAV2 vector, but <10% for all other vectors (Fig. 2b). Similar results were observed using enriched bone marrow-derived immature DCs (Fig. 2c). Of note, the AAV5 vector strongly transduced both bone marrow-derived CD11c⁺ cells and CD11c⁻ cells (Fig. 2c). Further study demonstrated that AAV5 transduced most unpurified bone marrow cells, whereas AAV2 was much less effective and other AAV serotypes largely ineffective (Fig. 3). AAV5 was also effective at transducing T cells (>85% of CD3⁺ cells) and macrophages (>30% of CD11b⁺ cells), but less than 10% of T cells and macrophages were transduced by other AAV serotypes (Fig. 3). However, there was no significant difference in the abilities of various vectors to transduce B cells (<15%).

Strong tropism of AAV5 for human DCs. To explore the transduction efficiency of AAV5 for human target cells, DCs were prepared from human PBMCs. At an infection dose of

10^5 vp/cell, 26.8% of enriched human CD11⁺ DCs were transduced by AAV5, but less than 5% of DCs were transduced by other serotypes (Fig. 4). The cellular tropism of AAV5 was also examined by flow cytometry. AAV5 infected 56.4% of CD3⁺ T cells (Fig. 4) and 23.5% of CD11b⁺ macrophages (Fig. 4). However, other serotype vectors were poorly transduced into both T cells and macrophages (<5%, Fig. 4). No significant difference in transduction of CD19⁺ B cells was observed among AAV serotype vectors (<10% of B cells). In general, human DCs, macrophages, and T cells were transduced less effectively by AAV5 than were murine cells, perhaps reflecting differences in AAV5 receptor expression between these two species.

Similar immunogenicities of AAV vectors produced by HEK293 cells and insect cells. Difficulty in producing high-titered AAV stocks has limited the clinical utility of this class of vectors. To resolve the problem, AAV vectors have been produced utilizing baculovirus in insect cells (42, 56, 58) and herpes simplex virus (8, 14). In this study, HEK293 cells were infected with 10^5 vp/cell of AAV-HIV vectors and the expression of AAV-HIV vectors was confirmed by Western blotting (Fig. 5a). HIV gene expression by AAV1 and AAV2 vectors was slightly stronger than that by other serotype vectors. The

FIG. 4. Transduction of enriched human DCs and unpurified PBMCs by AAV serotype vectors. Human enriched DCs or PBMCs were transduced with 10^5 vp/cell of AAV-LacZ vectors. Two days after transduction, the DCs were treated with FDG and anti-human CD11c Ab, and PBMCs were treated with FDG and anti-human CD3 (T cells), anti-human CD11b (macrophages), or anti-human CD19 (B cells) antibody followed by flow cytometric analysis. Panels show results from one of three independent experiments.

abilities to produce three AAV serotypes (AAV1, AAV2, and AAV5) in insect cells and in HEK293 cells were compared. Expression levels of insect cell-produced AAV vectors similar to those of HEK293-produced corresponding AAV vectors were observed. Again, as seen in Fig. 6, similar cell-mediated immune responses were elicited by the corresponding AAV vectors. However, AAV vectors derived from insect cells were slightly more effective at inducing humoral immune responses than vectors derived from HEK293 cells (Fig. 5b). This may be due to vector contamination by baculovirus components, since baculovirus itself can have an adjuvant effect on vaccine-induced immune responses (1, 22).

AAV-HIV immunization stimulates a humoral immune response. To explore the immunogenicity of the AAV vectors, BALB/c mice were immunized three times with 10^{10} vp of various AAV-HIV vectors. The resultant HIV-specific serum Ab response was examined 1 month after the last boost. The strongest HIV-specific serum IgG response was generated in mice immunized with the AAV5-HIV vector; the poorest humoral responses were observed in mice immunized with AAV3-HIV or AAV4-HIV (Fig. 5b). AAV1-HIV, AAV7-HIV, and AAV8-HIV induced intermediate humoral responses (Fig. 5b).

AAV-HIV immunization stimulates a cellular immune response. The induction of HIV-specific IFN- γ -secreting cells was then examined in the immunized mice. As observed for humoral immunity, animals immunized with the AAV5-HIV

vector generated the strongest cellular immune response (1,500 SFC/million cells). The AAV1, AAV2, AAV7, and AAV8 HIV vectors also stimulated >300 IFN- γ -secreting SFC/million spleen cells, whereas the AAV3- and AAV4-HIV vectors elicited significantly weaker cellular responses ($P < 0.05$, Fig. 6a). The AAV5-HIV produced by either HEK293 or insect cells induced significantly higher cellular immune responses than the AAV1-HIV produced by corresponding cells.

A tetramer binding assay was used to identify major histocompatibility complex class I-restricted HIV-specific T cells (3). Mice immunized with the AAV1-, AAV5-, and AAV7-HIV vectors induced strong HIV-specific CD8 $^{+}$ T-cell responses (>2%, Fig. 6b), and AAV2-HIV was intermediate (1.2%), while AAV3- and AAV4-HIV elicited only 0.4% HIV-specific CD8 $^{+}$ T cells.

An *in vivo* CTL assay was used to detect vaccine-elicited cell-mediated immune responses. Whereas the AAV3-, AAV4-, and AAV8-HIV vectors elicited approximately 40% CTL activity, the AAV1-, AAV5-, and AAV7-HIV vectors were significantly more effective (generally >50% activity), with the AAV2-HIV vector being intermediate (Fig. 6c).

DCs present HIV peptide to T cells *in vivo*. To examine whether DCs play a role in AAV-HIV-induced immune responses, DCs were enriched from the bone marrow of naïve mice. Enriched DCs were then treated with AAV5-LacZ, AAV1-HIV, AAV2-HIV, or AAV5-HIV vectors *in vitro* (10^5

FIG. 5. Expression of HIV gp160 and HIV-specific serum IgG titer by AAV serotype vectors. (a) HEK293 cells were transduced with AAV vectors carrying the HIV Env gp160 gene. Two days after infection, cell lysates were analyzed by Western blotting using anti-HIV Env MAb and anti-human β -actin MAb. (b) BALB/c mice (five mice/group) were immunized with AAV-HIV vectors on days 0, 14, and 28. HIV-specific serum IgG was measured 1 month after the final immunization. The BacAAV vectors were generated in insect cells, whereas other vectors were produced in HEK293 cells. The asterisks indicate significant differences between the two groups ($P < 0.05$).

vp/cell). The expression of HIV gp160 protein on the surface of mouse DCs was confirmed by anti-mouse HIV gp120 monoclonal antibody and anti-mouse CD11c antibody staining followed by flow cytometric analysis. HIV gp160 protein was detected in 13.5%, 19.4%, and 65.2% of CD11c⁺ DCs which were transduced with AAV1-HIV, AAV2-HIV, and AAV5-HIV vectors, respectively (Fig. 7a). On the other hand, enriched mouse DCs were transduced with AAV-HIV vectors and injected into naïve recipients. Seven days later, HIV-specific tetramer binding CD8⁺ cells were quantified using the tetramer assay. Recipients of the AAV2-HIV (0.6%)- and AAV5-HIV (2.1%)-transduced cells had significantly higher HIV peptide-binding CD8⁺ T cells than the AAV-LacZ-treated control (0.0%) (Fig. 7b). In contrast, a weak immune response was observed in recipients of AAV1-HIV vector-transduced cells (0.1%).

DISCUSSION

The present study demonstrates that AAV5 is a superior vector for achieving humoral and cellular immune responses, and the immunogenicity of AAV vectors depends on their tropism for both antigen-presenting cells (APCs) (such as DCs) and non-antigen-presenting cells (such as muscular cells). Consistent with previous studies, AAV-HIV vectors of different serotypes had distinct effects on the induction of HIV-specific humoral and cell-mediated immune responses (10, 17, 20, 28, 31, 38, 40, 53, 65, 66). However, most of these studies examined the durability of transgene expression after i.m. administration of the AAV vector but did not typically monitor cell-mediated immune responses against the encoded antigen (19, 32, 61). In contrast to studies in which the AAV vector encoded a self protein (as in gene therapy) or in which a

FIG. 7. Immune responses induced by ex vivo DC transduction. Mouse enriched DCs were transduced with 10^5 vp/cell of AAV-HIV vectors for 2 days. The cells were stained with PE-conjugated anti-mouse CD11c antibody plus mouse anti-HIV gp120 antibody followed by staining with FITC-conjugated anti-mouse IgG. The HIV gp160 expression of DC surface was analyzed by flow cytometry (a). Enriched mouse DCs were transduced with AAV-HIV vectors for 2 h, washed with PBS (–), and injected intravenously into recipient BALB/c mice (five mice/group). HIV-specific responses were detected using the tetramer assay 1 week after administration. Dot plots show results from individual representative animals, while the data shown in the upper right quadrant represent the averages of five mice/group (b). Neg. Con., negative control.

neoantigen was used to evaluate long-term expression (such as β -galactosidase), the immune response elicited by our HIV Env gp160-encoding vector was quite strong (10, 17, 20, 28, 31, 38, 40, 53, 65, 66).

Most currently used AAV vectors for vaccine or gene therapy are based on the AAV2 serotype (10, 17, 20, 28, 31, 38, 40, 53, 65, 66). The current work compared the immunogenicity of AAV2-HIV to that of other AAV serotype-based vectors and found that the AAV5 vector induced the strongest cellular and humoral immune responses. This finding may help in the development of novel AAV vector-based vaccines, particularly because natural immunity to AAV5 is rare (30). Of note, while we used a prime/boost regimen involving repeated administration of the same AAV serotype vector, it may be even more effective to prime with one serotype and boost with another (since neutralizing Abs raised against the first vector are unlikely to cross-react with a different serotype) (48).

Following vaccination with the AAV vector, antigen-specific immune responses can be induced through at least two pathways. In one of the pathways, the vaccine vector directly infects APCs, such as DCs, where the encoded antigen is expressed. The antigen is then processed and presented by APCs to T cells (Fig. 7) (65). The percentage of HIV gp160⁺ CD11c⁺ cells in Fig. 7a was lower than the percentage of FDG⁺ CD11c⁺ cells in Fig. 2c. This may be due to the presentation of HIV gp160 peptides by DCs present in culture. In the other pathway, the vaccine vector infects non-APCs, such as muscle cells. APCs take up the antigen expressed by the infected cells and present peptides from the exogenous antigen to T cells by major histocompatibility complex class I-restricted cross-presentation. It has been known that adenovirus vectors may use both pathways; however, AAV2 relies on the latter pathway due to a low efficiency of transfection of DCs (53). Current findings indicate that AAV1,

FIG. 6. HIV-specific cell-mediated immune responses induced by AAV vector vaccination. BALB/c mice (five mice/group) were immunized with AAV-HIV vectors on days 0, 14, and 28. Five mice per group for the IFN- γ ELISPOT and tetramer assay and five mice per group for the in vivo CTL assay were used. The HIV-specific IFN- γ ELISPOT assay was performed (a), the percentage of HIV-specific tetramer binding CD8⁺ cells was determined (b), and the in vivo CTL assay was performed (c) 2 weeks after the final immunization. BacAAV vectors were generated in insect cells, whereas other AAV vectors were generated in HEK293 cells. Asterisks indicate significant differences between the two groups ($P < 0.05$). Panels b and c show results from individual representative animals, while the data represent the averages of five mice/group.

AAV7, and AAV8 vectors preferentially infect muscle cells, whereas the AAV5 vector optimally infected DCs (Fig. 1 to 4 and 7). Following i.m. administration, all four vectors induced higher HIV-specific immunogenicity than the AAV2 vector (Fig. 5 and 6).

DCs are primarily responsible for stimulating resting naïve T lymphocytes and initiating a CTL response (5). Immature DCs residing in the peripheral tissues capture foreign antigens, mature, and then migrate to secondary lymphoid organs, where the processed antigen is presented. To determine whether DCs might contribute to the immune responses induced by the AAV-HIV vector, enriched DCs were transduced with the AAV5-HIV vector and transferred into naïve mice. As seen in Fig. 7b, recipients generated HIV-specific tetramer binding CD8⁺ T cells. These results demonstrate that DCs can present vector-encoded antigen to naïve T cells efficiently. In this context, the levels of immune response induced by the AAV1-HIV, AAV2-HIV, and AAV5-HIV vectors correlated with their tropism for DCs (70).

A number of studies show that recombinant AAV vectors can be used to transduce DCs (2, 13, 32, 35, 39, 46, 49, 53, 70). Current results document that AAV5 can transfect mouse and human DCs much more efficiently than other AAV serotype vectors (Fig. 2 to 4). In addition, AAV5 was efficiently transduced into T cells and macrophages (Fig. 3 and 4), which may be useful for gene therapy of diseases involving hematopoietic cells (4, 26, 43, 57, 59, 69).

Eight AAV serotypes (AAV1 to AAV8) have been described, with each serotype having unique binding and cell tropism characteristics (6, 11, 12, 21, 44, 50, 60). A primary coreceptor for AAV5 is sialic acid, while the platelet-derived growth factor receptor is involved in the binding and cell entry of AAV5 (15). Platelet-derived growth factor receptor is mainly expressed on fibroblasts, smooth muscle cells, glial cells, and chondrocytes but not on hematopoietic cells. Surprisingly, we found that AAV5 was efficiently transduced into hematopoietic cells (Fig. 3 and 4), suggesting that another receptor(s) may be used by AAV5 for cell entry.

The AAV2 vector can be produced in insect cells by using baculovirus expression vectors in suspension culture, a strategy that is amenable to easy scale-up (58). In this study, AAV1, AAV2, and AAV5 vectors expressing the HIV gp160 gene were prepared using either insect cells or HEK293 cells. Similar immune responses were obtained using vectors produced by either method (Fig. 5b and 6), indicating that insect cell-produced AAV vectors should be considered for the large-scale preparation of AAV vectors.

In summary, this is the first report that systematically compares DC tropism and immunogenicity of AAV serotype vectors. Results show that AAV5 vectors can efficiently transduce DCs and produce stronger antigen-specific immune responses than other AAV vectors. Thus, AAV5-based vectors deserve further consideration for clinical vaccine development and immune therapy.

ACKNOWLEDGMENTS

We are grateful to M. Kawano for her technical assistance and A. De La Fuente for her secretarial assistance. We also extend our appreciation to J. M. Wilson and G. P. Gao for providing helper plasmids of AAV7 and AAV8.

This work was partially supported by a grant-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan and the Japanese National Institute of Biomedical Innovation (no. 05-1).

REFERENCES

1. Abe, T., H. Hemmi, H. Miyamoto, K. Moriishi, S. Tamura, H. Takaku, S. Akira, and Y. Matsuura. 2005. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. *J. Virol.* 79:2847–2858.
2. Aldrich, W. A., C. Ren, A. F. White, S. Z. Zhou, S. Kumar, C. B. Jenkins, D. R. Shaw, T. V. Strong, P. L. Triozzi, and S. Ponnazhagan. 2006. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. *Gene Ther.* 13:29–39.
3. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274:94–96.
4. Babcock, A. M., D. Standing, K. Bullshields, E. Schwartz, C. M. Paden, and D. J. Poulsen. 2005. In vivo inhibition of hippocampal Ca²⁺/calmodulin-dependent protein kinase II by RNA interference. *Mol. Ther.* 11:899–905.
5. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. *Nature* 392:245–252.
6. Bantel-Schaal, U., H. Delius, R. Schmidt, and H. zur Hausen. 1999. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. *J. Virol.* 73:939–947.
7. Behboudi, S., D. Chao, P. Kleenerman, and J. Austyn. 2000. The effects of DNA containing CpG motif on dendritic cells. *Immunology* 99:361–366.
8. Booth, M. J., A. Mistry, X. Li, A. Thrasher, and R. S. Coffin. 2004. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. *Gene Ther.* 11:829–837.
9. Boucher, D. W., W. P. Parks, and J. L. Melnick. 1970. A sensitive neutralization test for the adeno-associated satellite viruses. *J. Immunol.* 104:555–559.
10. Brockstedt, D. G., G. M. Podsakoff, L. Fong, G. Kurtzman, W. Mueller-Ruchholtz, and E. G. Engleman. 1999. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. *Clin. Immunol.* 92:67–75.
11. Chiorini, J. A., F. Kim, L. Yang, and R. M. Kotin. 1999. Cloning and characterization of adeno-associated virus type 5. *J. Virol.* 73:1309–1319.
12. Chiorini, J. A., L. Yang, Y. Liu, B. Safer, and R. M. Kotin. 1997. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. *J. Virol.* 71:6823–6833.
13. Chiriva-Internati, M., Y. Liu, E. Salati, W. Zhou, Z. Wang, F. Grizzi, J. J. Roman, S. H. Lim, and P. L. Hermonat. 2002. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. *Eur. J. Immunol.* 32:30–38.
14. Conway, J. E., C. M. Rhys, I. Zolotukhin, S. Zolotukhin, N. Muzyczka, G. S. Hayward, and B. J. Byrne. 1999. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type 1 vector expressing AAV-2 Rep and Cap. *Gene Ther.* 6:986–993.
15. Di Pasquale, G., B. L. Davidson, C. S. Stein, I. Martins, D. Scudiero, A. Monks, and J. A. Chiorini. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. *Nat. Med.* 9:1306–1312.
16. Duan, D., P. Sharma, J. Yang, Y. Yue, L. Dudus, Y. Zhang, K. J. Fisher, and J. F. Engelhardt. 1998. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. *J. Virol.* 72:8568–8577.
17. During, M. J., R. Xu, D. Young, M. G. Kaplitt, R. S. Sherwin, and P. Leone. 1998. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. *Nat. Med.* 4:1131–1135.
18. Fan, D. S., M. Ogawa, K. I. Fujimoto, K. Ikeguchi, Y. Ogasawara, M. Urabe, M. Nishizawa, I. Nakano, M. Yoshida, I. Nagatsu, H. Ichinose, T. Nagatsu, G. J. Kurtzman, and K. Ozawa. 1998. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. *Hum. Gene Ther.* 9:2527–2535.
19. Flotte, T. R., S. A. Afione, C. Conrad, S. A. McGrath, R. Solow, H. Oka, P. L. Zeitlin, W. B. Guggino, and B. J. Carter. 1993. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. *Proc. Natl. Acad. Sci. USA* 90:10613–10617.
20. Gallez-Hawkins, G., X. Li, A. E. Franck, L. Thao, S. F. Lacey, D. J. Diamond, and J. A. Zaia. 2004. DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. *Vaccine* 23:819–826.
21. Gao, G. P., M. R. Alvira, L. Wang, R. Calcedo, J. Johnston, and J. M. Wilson. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc. Natl. Acad. Sci. USA* 99:11854–11859.
22. Gronowski, A. M., D. M. Hilbert, K. C. Sheehan, G. Garotta, and R. D. Schreiber. 1999. Baculovirus stimulates antiviral effects in mammalian cells. *J. Virol.* 73:9944–9951.

23. Hacker, U. T., L. Wingenfeld, D. M. Kofler, N. K. Schuhmann, S. Lutz, T. Herold, S. B. King, F. M. Gerner, L. Perabo, J. Rabinowitz, D. M. McCarty, R. J. Samulski, M. Hallek, and H. Buning. 2005. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. *J. Gene Med.* 7:1429–1438.
24. Halbert, C. L., J. M. Allen, and A. D. Miller. 2001. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. *J. Virol.* 75:6615–6624.
25. Halbert, C. L., E. A. Rutledge, J. M. Allen, D. W. Russell, and A. D. Miller. 2000. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. *J. Virol.* 74:1524–1532.
26. Han, W., M. Wind-Rotolo, R. L. Kirkman, and C. D. Morrow. 2004. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. *Virology* 330:221–232.
27. Handa, A., S. Muramatsu, J. Qiu, H. Mizukami, and K. E. Brown. 2000. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. *J. Gen. Virol.* 81:2077–2084.
28. Hara, H., A. Monsonogo, K. Yuasa, K. Adachi, X. Xiao, S. Takeda, K. Takahashi, H. L. Weiner, and T. Tabira. 2004. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. *J. Alzheimers Dis.* 6:483–488.
29. Herzog, R. W., J. N. Hagstrom, S. H. Kung, S. J. Tai, J. M. Wilson, K. J. Fisher, and K. A. High. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. *Proc. Natl. Acad. Sci. USA* 94:5804–5809.
30. Hildinger, M., A. Auricchio, G. Gao, L. Wang, N. Chirmule, and J. M. Wilson. 2001. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. *J. Virol.* 75:6199–6203.
31. Johnson, P. R., B. C. Schnepf, M. J. Connell, D. Rohne, S. Robinson, G. R. Krivulka, C. I. Lord, R. Zinn, D. C. Montefiori, N. L. Letvin, and K. R. Clark. 2005. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. *J. Virol.* 79:955–965.
32. Jooss, K., Y. Yang, K. J. Fisher, and J. M. Wilson. 1998. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. *J. Virol.* 72:4212–4223.
33. Jounai, N., K. Okuda, Y. Kojima, Y. Toda, K. Hamajima, K. Ohba, D. Klinman, and K. Q. Xin. 2003. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. *J. Gene Med.* 5:609–617.
34. Kay, M. A., C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, V. Arruda, F. Johnson, C. Scallan, E. Skarsgard, A. W. Flake, and K. A. High. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat. Genet.* 24:257–261.
35. Koppold, B., G. Sauer, H. Buning, M. Hallek, R. Kreienberg, H. Deissler, and C. Kurzeder. 2005. Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. *Int. J. Oncol.* 26:95–101.
36. Kotin, R. M., M. Siniscalco, R. J. Samulski, X. D. Zhu, L. Hunter, C. A. Laughlin, S. McLaughlin, N. Muzyczka, M. Rocchi, and K. I. Berns. 1990. Site-specific integration by adeno-associated virus. *Proc. Natl. Acad. Sci. USA* 87:2211–2215.
37. Lewin, A. S., K. A. Drenser, W. W. Hauswirth, S. Nishikawa, D. Yasumura, J. G. Flannery, and M. M. LaVail. 1998. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. *Nat. Med.* 4:967–971.
38. Liu, D. W., J. L. Chang, Y. P. Tsao, C. W. Huang, S. W. Kuo, and S. L. Chen. 2005. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. *Int. J. Cancer* 113:93–100.
39. Liu, Y., A. D. Santin, M. Mane, M. Chiriva-Internati, G. P. Parham, A. Ravaggi, and P. L. Hermonat. 2000. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. *J. Interferon Cytokine Res.* 20:21–30.
40. Manning, W. C., X. Paliard, S. Zhou, M. P. Bland, A. Y. Lee, K. Hong, C. M. Walker, J. A. Escobedo, and V. Dwarki. 1997. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. *J. Virol.* 71:7960–7962.
41. Manno, C. S., A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High, and B. Glader. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood* 101:2963–2972.
42. Meghroun, J., M. G. Aucoin, D. Jacob, P. S. Chahal, N. Arcand, and A. A. Kamen. 2005. Production of recombinant adeno-associated viral vectors using a baculovirus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. *Biotechnol. Prog.* 21:154–160.
43. Moore, M. D., M. J. McGarvey, R. A. Russell, B. R. Cullen, and M. O. McClure. 2005. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. *J. Gene Med.* 7:918–925.
44. Muramatsu, S., H. Mizukami, N. S. Young, and K. E. Brown. 1996. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. *Virology* 221:208–217.
45. Padron, E., V. Bowman, N. Kaludov, L. Govindasamy, H. Levy, P. Nick, R. McKenna, N. Muzyczka, J. A. Chiorini, T. S. Baker, and M. Agbandje-McKenna. 2005. Structure of adeno-associated virus type 4. *J. Virol.* 79:5047–5058.
46. Ponnazhagan, S., G. Mahendra, D. T. Curiel, and D. R. Shaw. 2001. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. *J. Virol.* 75:9493–9501.
47. Rabinowitz, J. E., F. Rolling, C. Li, H. Conrath, W. Xiao, X. Xiao, and R. J. Samulski. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. *J. Virol.* 76:791–801.
48. Rabinowitz, J. E., and R. J. Samulski. 2000. Building a better vector: the manipulation of AAV virions. *Virology* 278:301–308.
49. Ribas, A. 2005. Genetically modified dendritic cells for cancer immunotherapy. *Curr. Gene Ther.* 5:619–628.
50. Rutledge, E. A., C. L. Halbert, and D. W. Russell. 1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. *J. Virol.* 72:309–319.
51. Samulski, R. J., K. I. Berns, M. Tan, and N. Muzyczka. 1982. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. *Proc. Natl. Acad. Sci. USA* 79:2077–2081.
52. Santosuosso, M., X. Zhang, S. McCormick, J. Wang, M. Hitt, and Z. Xing. 2005. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. *J. Immunol.* 174:7986–7994.
53. Sarukhan, A., S. Camugli, B. Gjata, H. von Boehmer, O. Danos, and K. Jooss. 2001. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. *J. Virol.* 75:269–277.
54. Schnepf, B. C., K. R. Clark, D. L. Klemanski, C. A. Pacak, and P. R. Johnson. 2003. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. *J. Virol.* 77:3495–3504.
55. Snyder, R. O., C. H. Miao, G. A. Patijn, S. K. Spratt, O. Danos, D. Nagy, A. M. Gown, B. Winther, L. Meuse, L. K. Cohen, A. R. Thompson, and M. A. Kay. 1997. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat. Genet.* 16:270–276.
56. Sollerbrant, K., J. Elmen, C. Wahlestedt, J. Acker, H. Leblois-Prehaud, M. Latta-Mahieu, P. Yeh, and M. Perricaudet. 2001. A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. *J. Gen. Virol.* 82:2051–2060.
57. Tomar, R. S., H. Matta, and P. M. Chaudhary. 2003. Use of adeno-associated viral vector for delivery of small interfering RNA. *Oncogene* 22:5712–5715.
58. Urabe, M., C. Ding, and R. M. Kotin. 2002. Insect cells as a factory to produce adeno-associated virus type 2 vectors. *Hum. Gene Ther.* 13:1935–1943.
59. Xia, H., Q. Mao, S. L. Eliason, S. Q. Harper, I. H. Martins, H. T. Orr, H. L. Paulson, L. Yang, R. M. Kotin, and B. L. Davidson. 2004. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. *Nat. Med.* 10:816–820.
60. Xiao, W., N. Chirmule, S. C. Berta, B. McCullough, G. Gao, and J. M. Wilson. 1999. Gene therapy vectors based on adeno-associated virus type 1. *J. Virol.* 73:3994–4003.
61. Xiao, X., J. Li, and R. J. Samulski. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. *J. Virol.* 70:8098–8108.
62. Xin, K. Q., Y. Hoshino, Y. Toda, S. Igimi, Y. Kojima, N. Jounai, K. Ohba, A. Kushi, M. Kiwaki, K. Hamajima, D. Klinman, and K. Okuda. 2003. Immunogenicity and protective efficacy of orally administered recombinant *Lactococcus lactis* expressing surface-bound HIV Env. *Blood* 102:223–228.
63. Xin, K. Q., N. Jounai, K. Someya, K. Honma, H. Mizuguchi, S. Naganawa, K. Kitamura, T. Hayakawa, S. Saha, F. Takeshita, K. Okuda, M. Honda, and D. M. Klinman. 2005. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. *Gene Ther.* 12:1769–1777.
64. Xin, K. Q., Y. Kumamoto, N. Jounai, Y. Kojima, K. Hamajima, and K. Okuda. 2002. Recombinant vaccinia virus (WR strain) may not be suitable for ex vivo stimulation. *Vaccine* 21:5–6.
65. Xin, K. Q., T. Ooki, H. Mizukami, K. Hamajima, K. Okudela, K. Hashimoto, Y. Kojima, N. Jounai, Y. Kumamoto, S. Sasaki, D. Klinman, K. Ozawa, and K. Okuda. 2002. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. *Hum. Gene Ther.* 13:1571–1581.

66. **Xin, K. Q., M. Urabe, J. Yang, K. Nomiya, H. Mizukami, K. Hamajima, H. Nomiya, T. Saito, M. Imai, J. Monahan, K. Okuda, and K. Ozawa.** 2001. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. *Hum. Gene Ther.* **12**:1047–1061.
67. **Yoshida, A., R. Tanaka, T. Murakami, Y. Takahashi, Y. Koyanagi, M. Nakamura, M. Ito, N. Yamamoto, and Y. Tanaka.** 2003. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4⁺ T-cell origin. *J. Virol.* **77**:8719–8728.
68. **Zabner, J., M. Seiler, R. Walters, R. M. Kotin, W. Fulgeras, B. L. Davidson, and J. A. Chiorini.** 2000. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. *J. Virol.* **74**:3852–3858.
69. **Zhang, W., R. Singam, G. Hellermann, X. Kong, H. S. Juan, R. F. Lockey, S. J. Wu, K. Porter, and S. S. Mohapatra.** 2004. Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. *Genet. Vaccines Ther.* **2**:8.
70. **Zhang, Y., N. Chirmule, G. Gao, and J. Wilson.** 2000. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. *J. Virol.* **74**:8003–8010.